Atezolizumab

Atezolizumab
Description

Product Description

Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD-L2 with PD-1.

 

[accordions]
[accordion title= “Cell Research“]

Objective: Determine the binding of [111In]PD-L1-mAb to tumor cell lines. Cells: NCI-H2444(Lung Cancer cell line), MDAMB231(Breast Cancer cell line),etc. Concentrations: 1 μCi/100μl. Incubation Time: 1 h. Method: Incubating 1 μCi of [111In]PD-L1-mAb with 1×106cells (in triplicate for each cell line) for 1h at 37°C. PD-L1 blocking was performed by adding a 10-fold molar equivalent excess of the non-labeled mAb. After incubation, cells were washed three times with cold PBS prior to counting on an automated gamma counter.

[/accordion]

 

 

[accordions]
[accordion title= “Chemical Properties“]

Molecular Weight 145 kDa
CAS No. 1380723-44-3

[/accordion]

 

 

[accordions]
[accordion title= “References and Literature“]

1. Inman BA, et al. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1886-1890.2. Deng R, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8(3):593-603.3. Zheng Y, et al. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered. 2017 Jul 4;8(4):367-373.4. Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7.

[/accordion]